Annual Drug Patent Expirations for MIRVASO
Mirvaso is a drug marketed by Galderma Labs Lp and is included in one NDA. It is available from one supplier. There are twelve patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for MIRVASO.
This drug has ninety-nine patent family members in thirty-one countries.
The generic ingredient in MIRVASO is brimonidine tartrate. One supplier is listed for this compound. Additional details are available on the brimonidine tartrate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
